Document is current
Any future updates will be listed below
-
Authors
Arenas, Enrique J. https://orcid.org/0000-0001-7076-2666
Martínez-Sabadell, Alex https://orcid.org/0000-0002-9477-1396
Rius Ruiz, Irene https://orcid.org/0000-0002-6097-7572
Román Alonso, Macarena https://orcid.org/0000-0001-8128-9528
Escorihuela, Marta
Luque, Antonio
Fajardo, Carlos Alberto
Gros, Alena
Klein, Christian https://orcid.org/0000-0001-7594-7280
Arribas, Joaquín https://orcid.org/0000-0002-0504-0664
- License Information
-
More Information
Article History
Received: 28 October 2020
Accepted: 24 January 2021
First Online: 23 February 2021
Competing interests
: C.K. declares employment, stock ownership, and patents with Roche. A.G. reports receiving funding from Novartis, VCNBiosciences and Merck KGaA, has received speaker honoraria from Roche, and has consulted for Achilles Therapeutics, Neon Therapeutics, Genentech, PACT Pharma and Oxford Immunotherapy. J.A. has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini. The remaining authors declare no competing interests.
